Business
Notice of Cipher Pharmaceuticals Q2 2019 Conference Call
Notice of Cipher Pharmaceuticals Q2 2019 Conference Call Canada NewsWire OAKVILL...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nNotice of Cipher Pharmaceuticals Q2 2019 Conference Call\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nOAKVILLE, ON, July 30, 2019\n\n\n\nOAKVILLE, ON, July 30, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) (\"Cipher\" or \"the Company\") today announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019. \nCONFERENCE CALL DETAILS\nDATE:\nFriday, August 9, 2019\nTIME:\n8:30 a.m. ET\nDIAL IN NUMBER:\n(416) 764-8609 or (888) 390-0605\nCONFERENCE ID:\n27295490\nREPLAY:\n(416) 764-8677 or (888) 390-0541 (playback code 295490 #)\nAvailable until midnight (ET) Friday, August 16, 2019\nWEBCAST: \nThe audio webcast can be accessed at https://cipher.investorroom.com/ under Investor Relations or at\nhttps://event.on24.com/wcc/r/2058250/C6C81F9C26A51E884F4522F2E100CC59\n \nAbout Cipher Pharmaceuticals Inc.Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com. \nSOURCE Cipher Pharmaceuticals Inc.\n\n\n\nView original content: http://www.newswire.ca/en/releases/archive/July2019/30/c7950.html\n\n\n\n\nInvestors, James Bowen...